Dec 12 (Reuters) - Arcus Biosciences (RCUS.N), opens new tab said on Friday it would stop a late-stage study testing its experimental cancer drug combination in patients with advanced stomach and ...

Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer. Arcus ...

Arcus Biosciences, Inc. (NYSE:RCUS) on Friday announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc. (NASDAQ: GILD), due to futility. • ...

A key late-stage trial of Arcus Biosciences and Gilead Sciences' anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several studies of the drug. The ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory ...

The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futility Arcus is continuing to expand its development program for ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Arcus Biosciences Inc (RCUS) stock reached a significant milestone, hitting a 52-week high of 26.32 USD, representing a remarkable 304% increase from its 52-week low of 6.50 USD. According to ...

Arcus Biosciences' estimated fair value is US$41.75 based on 2 Stage Free Cash Flow to Equity Arcus Biosciences is estimated to be 39% undervalued based on current share price of US$25.56 The US$32.22 ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Fintel reports that on October 20, 2025, Wells Fargo maintained coverage of Arcus Biosciences (NYSE:RCUS) with a Overweight recommendation. Analyst Price Forecast Suggests 70.28% Upside As of ...

Investing.com -- Arcus Biosciences (NYSE:RCUS) stock surged 15% Monday after the clinical-stage biopharmaceutical company reported encouraging new data for its kidney cancer drug casdatifan, showing ...